Strategic Analysis of the Global Dry Age-Related Macular Degeneration Market from 2024 to 2032

The Dry Age-Related Macular Degeneration (AMD) Market size, valued at USD 4.83 billion in 2023, is anticipated to reach USD 10.57 billion by 2032, growing at a compound annual growth rate (CAGR) of 9.1% from 2024 to 2032. The market's growth is driven by the increasing elderly population, advancements in treatment options, and a higher prevalence of age-related vision disorders globally.

Market Overview

Dry AMD is a progressive eye condition that leads to a gradual loss of central vision, typically affecting individuals over 50. This type of macular degeneration results from the breakdown of the light-sensitive cells in the macula, causing visual impairment that impacts daily activities such as reading, driving, and recognizing faces. With the rising number of aging populations worldwide, the demand for AMD treatments has increased significantly, promoting a robust market for effective therapeutic solutions.

Get A Free Sample Report on Endoprosthesis Market @ snsinsider.com/sample-request/2625

Key Market Drivers

Growing Geriatric Population: A rapidly aging global population, particularly in regions like North America, Europe, and parts of Asia, significantly contributes to the increasing prevalence of AMD. According to the World Health Organization (WHO), the number of people aged 60 and above is expected to double by 2050, intensifying the demand for advanced eye-care solutions.
Increasing Prevalence of AMD and Vision Disorders: Dry AMD is a leading cause of vision loss among individuals over 50, with millions worldwide affected. Factors such as lifestyle changes, genetics, and environmental influences increase the susceptibility to this condition, driving market demand.
Advancements in Therapeutics and Diagnostics: Novel diagnostic methods, including optical coherence tomography (OCT) and genetic testing, have improved early AMD detection. Additionally, new therapeutic developments such as complement inhibitors and regenerative cell therapies are expanding treatment options and improving patient outcomes, propelling market growth.
Rising Awareness and Screening Programs: Increased awareness of AMD, along with regular screening initiatives, encourages early diagnosis and timely intervention, which is crucial for managing dry AMD. Government programs and non-profit organizations contribute to public awareness and education, boosting market demand.

Make an inquiry on the Endoprosthesis Market Report @ snsinsider.com/enquiry/2625

Market Segmentation

By Stages
- Early Age-Related Macular Degeneration
- Intermediate Age-Related Macular Degeneration
- Late Age-Related Macular Degeneration

By Age Group

Above 40 Years
Above 60 Years
Above 75 Years

By Diagnosis And Treatment

Treatment
Diagnosis

By Route Of Administration

Oral
Injectables

By End User

Hospital & Clinics
Diagnostic Centers
Academic Research Institutes
Others

Regional Insights

The North American market dominates, supported by a well-developed healthcare infrastructure, widespread awareness of AMD, and high demand for advanced ophthalmology treatments. Europe is also experiencing considerable growth due to the large elderly population and high healthcare expenditure. The Asia-Pacific region is poised for rapid growth, driven by an increasing elderly population, improving healthcare facilities, and growing awareness of AMD in countries like Japan, China, and India.

Key Market Players

Treatment Providers

Bayer AG
Pfizer Inc.
Amgen Inc.
Biogen
Novartis AG
F. Hoffmann-La Roche Ltd
Samsung Bioepis
Bausch Health Companies Inc.
Regeneron Pharmaceuticals Inc.
Santen Pharmaceuticals Inc.
Allergan plc
Alimera Sciences Inc.
Phio Pharmaceuticals Corp
Iveric Bio
Belite Bio Inc.

Diagnosis Providers

Bausch Health Companies Inc.
Alimera Sciences Inc.
Ocumension Therapeutics Co. Ltd
Iveric Bio

Device Manufacturers

Bausch Health Companies Inc.
Regeneron Pharmaceuticals Inc.
Biogen
Eyestem Research Pvt Ltd
Kubota Vision Inc.

Market Trends and Opportunities

Innovative Therapeutic Approaches: Development in therapies like complement inhibitors, which aim to reduce inflammation associated with AMD, is expected to significantly improve treatment outcomes. These treatments are undergoing clinical trials and may provide viable options beyond traditional supplements and injections.
Potential of Gene Therapy: Emerging research in gene therapy offers promising results for treating AMD by targeting specific genes that contribute to macular degeneration. Successful implementation could lead to breakthrough treatments with long-lasting effects.
Artificial Intelligence in Early Detection: AI-powered diagnostic tools are being increasingly applied to analyze retinal images and detect early signs of AMD, providing an accurate and efficient approach to early diagnosis. This trend is expected to support disease management and prevent progression.

Conclusion

The Dry Age-Related Macular Degeneration Market is on a growth trajectory, driven by a combination of increasing elderly populations, advanced diagnostics, and innovative therapeutics. As key players invest in research and new technologies, the market is well-positioned to deliver solutions that improve the quality of life for AMD patients and mitigate the burden of vision impairment.

Buy a Single-User PDF of Endoprosthesis Market @ snsinsider.com/checkout/2625

About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us:
Akash Anand – Head of Business Development & Strategy
info@snsinsider.com
Phone: +1-415-230-0044 (US) | +91-7798602273 (IND)